RankingsPricing
  1. US-listed companies
  2. NeuBase Therapeutics, Inc.
  3. Financials
  4. Stock-based compensation

NeuBase Therapeutics, Inc.NBSE

Market cap
$1.41M
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Sep 30, 20223-21.61%
Sep 30, 20214-28.84%
Sep 30, 20205-46.91%
Sep 30, 201910+1014.79%
Sep 30, 20181-32.16%
Sep 30, 20171-55.59%
Sep 30, 20163-18.61%
Sep 30, 20154+72.56%
Sep 30, 20142+13.25%
Sep 30, 20132+68.74%
Sep 30, 20121+59.81%
Sep 30, 20111

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)